HOOKIPA Biotech GmbH
Hookipa Biotech GmbH
Helmut-Qualtinger-Gasse 2
Vienna
1030
Austria
Website: http://www.hookipapharma.com/
About HOOKIPA Biotech GmbH
61 articles about HOOKIPA Biotech GmbH
-
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
4/20/2022
HOOKIPA Pharma Inc. today announced the appointment of Tim Reilly, Ph.D. to its Board of Directors, effective immediately.
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
4/13/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers.
-
HOOKIPA to Participate in the Kempen Life Sciences Conference - Apr 13, 2022
4/13/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 - 21, 2022.
-
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
3/24/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and provided a corporate update for the fourth quarter and full year 2021, as well as outlook for 2022.
-
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
3/22/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that Klaus Orlinger, Ph.D. has been promoted to Chief Scientific Officer.
-
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
3/17/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2021 financial results before the market opens on Thursday, March 24, 2022.
-
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
3/8/2022
HOOKIPA Pharma Inc. announced that preclinical, translational, and clinical biomarker data from its oncology pipeline have been selected for four poster presentations at the 2022 American Association for Cancer Research Annual Meeting, taking place April 8-13.
-
HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
3/2/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced the pricing of an underwritten public offering of 21,700,000 shares of its common stock and 15,800 shares of its non-voting Series A-1 convertible preferred stock.
-
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
3/1/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that it intends to offer and sell shares of its common stock and shares of its non-voting Series A convertible preferred stock in an underwritten public offering.
-
HOOKIPA Pharma Inc.’s shares have soared after stating it amended and restated a collaboration and license agreement with Gilead Sciences to develop immunotherapies against HIV.
-
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV
2/15/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), today announced it has entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).
-
HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
2/9/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, February 14 - 18, 2022.
-
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
1/18/2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of 1st-line advanced/metastatic Human Papillomavirus 16 Positive (HPV16+) squamous cell head and neck cancers (HNSCC) in a Phase 2 arm of the ongoing Phase 1/2 trial (NCT04180215).
-
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
1/4/2022
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the Company will present at the virtual H.C. Wainwright BioConnect Conference, January 10 - 13, 2022.
-
HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
12/3/2021
HOOKIPA Pharma Inc. today announced that HOOKIPA’s management team will participate in virtual investor meetings and present at The JMP Securities Hematology and Oncology Summit that will be held December 6-7, 2021.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
11/12/2021
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that HOOKIPA’s management team will participate in the Stifel 2021 Virtual Healthcare Conference that will be held November 15th – 17, 2021.
-
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
11/10/2021
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and business highlights for the third quarter of 2021.
-
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
11/9/2021
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced it is advancing HB-201 to Phase 2, to be evaluated in combination with pembrolizumab as 1st- or 2nd-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).